Surya Bhatt Presents Results of NOTUS Trial for COPD Treatment | 2024 ATS
At the 2024 American Thoracic Society conference, Surya Bhatt, MD, director of the Lung Imaging Lab at the University of Alabama of Birmingham discussed the NOTUS trial, a second phase three trial for treating COPD with type two inflammation using dupilumab, following the BOREAS trial.
At the 2024 American Thoracic Society conference, Surya Bhatt, MD, director of the Lung Imaging Lab at the University of Alabama of Birmingham discussed the NOTUS trial, a second phase three trial for treating COPD with type two inflammation using dupilumab, following the BOREAS trial.
He explained that a second trial was mandated by the FDA to replicate results and confirm efficacy.
The NOTUS trial showed a 34% reduction in exacerbations, similar to the 30% reduction in the BOREAS trial, and similar improvements in lung function.
While the interim analysis of the NOTUS trial showed fewer statistically significant secondary outcomes due to fewer subjects, the overall findings were consistent.
Bhatt also shared additional data on quality of life and symptom burden, extending beyond what was first reported in November 2023.
Ways Healthcare Differs Depending on the State an Immigrant Child Resides In | ATS 2024
May 22nd 2024Undocumented individuals are ineligible for the Affordable Care Act (ACA) or federally funded Medicaid, but some states offer state-sponsored coverage for certain immigration statuses, such as Temporary Protected Status.
Read More
Orangutan Health Offers Insights for Human Respiratory Disease | 2024 ATS
May 22nd 2024Speakers at the annual American Thoracic Society meeting discussed research looking at whether orangutan respiratory disease syndrome might have some of the same genetic causes as cystic fibrosis.
Read More
